Key result
Statins are linked to less anthracycline-induced cardiotoxicity but recent trials show conflicting results.
Why the study?
Cardioprotective mechanisms of statins remain incompletely understood and recent randomized controlled trials investigating statins for the primary prevention of anthracycline-induced cardiotoxicity have yielded contrasting results.
Does statin therapy prevent anthracycline-induced cardiotoxicity in cancer patients receiving anthracyclines?
Does statin therapy prevent anthracycline-induced cardiotoxicity in cancer patients receiving anthracyclines?
Statins may offer a cardioprotective effect against anthracycline-induced cardiotoxicity, though recent randomized trials present conflicting evidence on their efficacy in preserving LVEF.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“As cancer survivorship continues to improve, preventing cancer therapy–related cardiac dysfunction is crucial to reducing cardiovascular (CV) morbidity in survivors of cancer.”
Statins may warrant consideration to mitigate anthracycline cardiotoxicity; review leaves optimal use and mechanisms open for prospective trials.
PURPOSE OF REVIEW: The aim of this review is two-fold: (1) To examine the mechanisms by which statins may protect from anthracycline-induced cardiotoxicity and (2) To provide a comprehensive overview of the existing clinical literature investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity. RECENT FINDINGS: The underlying cardioprotective mechanisms associated with statins have not been fully elucidated. Key mechanisms related to the inhibition of Ras homologous (Rho) GTPases have been proposed. Data from observational studies has supported the beneficial role of statins for the primary prevention of anthracycline-induced cardiotoxicity. Recently, several randomized controlled trials investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity have produced contrasting results. Statins have been associated with a lower risk of cardiac dysfunction in cancer patients receiving anthracyclines. Further investigation with larger randomized control trials and longer follow-up periods are needed to better evaluate the long-term role of statin therapy and identify the subgroups who benefit most from statin therapy.
No takes yet. Share an insight, caveat, or question.
Bhasin et al. (2024) conducted a review in Anthracycline-induced cardiotoxicity. Statins vs. Placebo or control was evaluated on Cardiac dysfunction / Anthracycline-induced cardiotoxicity. Statins have been associated with a lower risk of cardiac dysfunction in cancer patients receiving anthracyclines, though recent randomized trials have shown contrasting results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: